Abstract
423 Phase 1 dose escalation, safety and pharmacokinetic study of IT-101 (CRLX101), a novel nanopharmaceutical containing camptothecin, in advanced solid tumor cancer patients
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have